Mineralys Therapeutics, Inc. MLYS Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Mineralys Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The official record: Mineralys Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mineralys Therapeutics, Inc.'s total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mineralys Therapeutics, Inc.'s total liabilities & equity?
- Mineralys Therapeutics, Inc. (MLYS) reported total liabilities & equity of $652.86M in Q1 2026.
- How has Mineralys Therapeutics, Inc.'s total liabilities & equity changed year-over-year?
- Mineralys Therapeutics, Inc.'s total liabilities & equity increased by 83.9% year-over-year, from $354.94M to $652.86M.
- What is the long-term trend for Mineralys Therapeutics, Inc.'s total liabilities & equity?
- Over 3 years (2022 to 2025), Mineralys Therapeutics, Inc.'s total liabilities & equity has grown at a 79.5% compound annual growth rate (CAGR), from $114.44M to $661.81M.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.